Boehringer Ingelheim Unveils New Trivalent Poultry Vaccine in Egypt
In a significant boost to the nation's poultry industry, Boehringer Ingelheim has announced the launch of its innovative trivalent vaccine, VAXXITEK® HVT+IBD+H5, scheduled for February 2025. The new vaccine promises comprehensive protection against three of the most critical diseases affecting poultry: Marek's disease, Infectious Bursal Disease (Gumboro), and H5 avian influenza.
Developed to address the heavy impact of H5 avian influenza—a highly contagious and notifiable zoonotic disease that has disrupted global poultry production and trade—the vaccine is designed for administration at the hatchery. This early intervention secures vital protection for chicks, effectively bridging the immunity gap between the waning maternal antibodies and the onset of active immunity.
Marek's disease, a viral condition that can cause tumors, paralysis, and high mortality rates, and Infectious Bursal Disease, known for inducing severe dehydration and productivity losses, have long challenged poultry producers worldwide. Vaccination against these diseases is already standard practice. However, the introduction of VAXXITEK® HVT+IBD+H5 marks the first instance globally where protection against H5 avian influenza is integrated into a single shot with these other critical vaccines.
Boehringer Ingelheim's breakthrough is underpinned by its COBRA (Computationally Optimised Broadly Reactive Antigen) technology, which has enabled the development of a unique antigen sequence. This innovation not only broadens the vaccine's coverage against multiple H5 avian influenza clades but also enhances its overall efficacy.
'The launch of VAXXITEK® HVT+IBD+H5 is another step forward in avian influenza prevention regarding both coverage and convenience,' said Taoufik Rawi, Head of Franchise, Poultry at Boehringer Ingelheim. 'Our customers must keep their flocks thriving and protect their chickens from health threats. With this three-in-one vaccine, we offer a quick and effective solution against the most prevalent H5 clades and two major poultry diseases.'
The vaccine's DIVA (Differentiating Infected from Vaccinated Animals) capability is a crucial feature, allowing authorities to distinguish between vaccinated and naturally infected birds—a vital tool in managing disease outbreaks. Dr. David Swayne, former Laboratory Director at the USDA and Adjunct Professor at the University of Georgia, USA, noted, 'The evolution of H5 avian influenza continues to pose a significant challenge for poultry health worldwide. Advancements in disease management strategies, including vaccination, play a crucial role in helping protect poultry flocks from its impact.'
Regional impact was underscored by industry leaders. Waleed El Mashak, Head of Animal Health IMETA at Boehringer Ingelheim, emphasized, 'As a region heavily impacted by avian influenza, the launch of VAXXITEK® HVT+IBD+H5 represents a critical advancement for poultry farmers across IMETA. Launching this vaccine in Egypt for the first time globally is a testament to our commitment to supporting sustainable poultry farming.'
Magdy Hassan, President of the Egyptian Veterinary Syndicate, described the introduction of the vaccine as 'a significant milestone, offering poultry farmers a powerful solution to enhance flock immunity and protect against major diseases, including H5 avian influenza.' Mahmoud El Mahdy, Country Head of Animal Health for North, East, and West Africa at Boehringer Ingelheim, added, 'This innovative vaccine is a game-changing approach to disease control, bolstering market stability and securing international trade opportunities. It underscores our ongoing commitment to advancing sustainable food production in Egypt.'
As Egypt's poultry sector continues to play a crucial role in the country's food security and economy, the launch of VAXXITEK® HVT+IBD+H5 is expected to deliver significant benefits for both producers and consumers, heralding a new era of enhanced disease control and sustainable poultry production.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mid East Info
09-05-2025
- Mid East Info
Can diet help with inflammatory bowel disease? - Middle East Business News and Information
Dubai, United Arab Emirates; May, 2025 — Inflammatory bowel disease IBD is a chronic inflammation of the digestive tract. It includes conditions such as ulcerative colitis and Crohn's disease. In this expert alert, Amanda Johnson, M.D. , a gastroenterologist at Mayo Clinic, helps explain IBD and whether diet can help. People with IBD may experience persistent symptoms like frequent diarrhea, weight loss, abdominal pain and fatigue. There is no cure and no exact cause, though researchers continue to look at how genes, the microbiome and environmental factors play a role in this chronic disease. 'Ulcerative colitis really tends to only involve the colon and be more of a superficial type inflammation; whereas Crohn's disease can impact anything in the intestine, essentially, from the mouth all the way down to the anus,' says Dr. Johnson. She says diet alone does not cause IBD. While some foods may reduce symptoms, there is no one proven diet to control inflammation. 'The right diet is probably different for each individual, based on the type of IBD that they have, the location of their disease, whether they've had surgeries or other complications,' says Dr. Johnson. Focus on fresh fruits and vegetables and whole grains. Avoid ultraprocessed foods, added sugars and animal fats. And drink plenty of water to stay hydrated. Diet does not replace medical treatment. Dr. Johnson says there are effective treatment options, so it is important to work with your healthcare team. 'The tenant of therapy we have are immune-suppressing-type therapies that try to target that inappropriate response to the intestines and then calm down that inflammation within the gut,' she says. About Mayo Clinic: Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.
Mid East Info
30-04-2025
- Mid East Info
Aster DM Healthcare Recognized as Great Place To Work™ in the Sultanate of Oman and other GCC countries - Middle East Business News and Information
Aster DM Healthcare, one of the largest integrated healthcare providers in the GCC, has been certified as a Great Place to Work® in the Middle East – including the Sultanate of Oman, UAE, Kingdom of Saudi Arabia and Qatar. This recognition reflects Aster's commitment to cultivating a workplace culture where employees feel valued, empowered, and proud to contribute to the organization's mission. Guided by its core values – Passion, Compassion, Integrity, Excellence, Unity, and Respect, Aster DM Healthcare places its people at the heart of its success. Aster's commitment to its brand promise, 'We'll Treat You Well,' goes beyond patients to include its employees as well. By recognizing their achievements, investing in skill development opportunities, and fostering open communication, Aster has cultivated an inclusive and supportive environment where employees thrive. The organization's culture of listening allows feedback from frontline staff to shape policies and enhance the work environment continuously. With these initiatives, Aster remains steadfast in its dedication to nurturing a workplace that empowers its people to deliver the best care. Aster has an employee base of 15,000+ across the GCC, one of the largest in the region here. A total of 76% of Aster's workforce rated the organization as a great place to work. This statistic highlights the strong sense of community and the inclusive, nurturing environment that has been built over the last 38 years. In Oman, the organization has 3 hospitals, 5 clinics, and 5 pharmacies. Commenting on the recognition, Alisha Moopen, Managing Director & Group CEO, Aster DM Healthcare said, 'Our people are our greatest strength, and this recognition affirms the culture we have built over the years and try to nourish every day. At Aster, we are committed to creating a workplace that values, inspires, and supports every individual, ensuring their growth aligns with the larger mission of the organization.' Jacob Jacob, Group Chief Human Resources Officer added, 'Our people will always be our competitive advantage. This certification is a testament to the strong sense of community we've built within Aster. Our efforts to create an environment of trust, respect, and growth have enabled our employees to feel deeply connected to our mission and values. This is just the beginning as we remain committed to nurturing their well-being and empowering their professional journeys.' 'Great Place To Work Certification is a highly coveted achievement that requires consistent and intentional dedication to the overall employee experience,' says Sarah Lewis-Kulin, the Vice President of Global Recognition at Great Place To Work. She emphasizes that Certification is the sole official recognition earned by the real-time feedback of employees regarding their company culture. 'By successfully earning this recognition, it is evident that Aster DM Healthcare stands out as one of the top companies to work for, providing a great workplace environment for its employees.' With a workforce of over 1,100+ in Oman alone, Aster DM Healthcare is united by individuals who embody its mission of providing accessible, affordable, and high-quality healthcare. The company plans to continue expanding career opportunities for Oman Nationals, implementing leadership development initiatives, and supporting local health campaigns aligned with the Sultanate's vision for a healthier future.
Mid East Info
26-04-2025
- Mid East Info
Kenvue Champions Role of Pharmacists at First Community Pharmacy Conference in the UAE - Middle East Business News and Information
Kenvue, the world's largest pure-play consumer health company by revenue and maker of Listerine, Nicorette, and Neutrogena, will join the UAE's first-ever community pharmacy conference as a gold sponsor. Led by the Emirates Pharmacy Society, this convening reflects a growing recognition of pharmacists as frontline healthcare providers — who are a familiar and reliable part of the community and play a vital role in promoting self-care to help ease pressure on wider healthcare systems. This extends beyond simply dispensing over-the-counter medications to providing invaluable and accessible medical advice. Kenvue will be sponsoring the event, where regional experts gather to discuss trends and challenges across Over-the-counter medicine (OTC), supply chain and insurance, helping advance the community pharmacy landscape. Rodney Smith, GCC Country Director at Kenvue, shared: 'Pharmacists are essential healthcare providers who significantly contribute to the depressurization of healthcare systems by enabling individuals to manage their health and wellbeing. As a company rooted in science and care, Kenvue believes pharmacists are not just dispensers of products, but rather the community's partners in prevention, education, and overall well-being. Supporting the sector through the IVPN network at the conference is part of Kenvue's broader effort to nurture community health and ensure that people across the region have access to reliable health guidance.' About Kenvue : Kenvue is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand Adhesive Bandages, Johnson's, Listerine, Neutrogena, and Tylenol, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that power in consumers' hands and earn a place in their hearts and homes.
